0% Complete
صفحه اصلی
/
اولین کنگره بین المللی رویکردهای نوین سبک زندگی، پیشگیری و درمان سرطان
Investigating the impact of cancer stem cell targeting in the process of breast cancer treatment
نویسندگان :
Reza Khosravi (دانشگاه علوم پزشکی شهید بهشتی) , Mobina Momeni Daraby (دانشگاه علوم پزشکی شهید بهشتی)
کلمات کلیدی :
Stem Cell،Targeting،Breast Cancer،Treatment
چکیده :
Introduction: Breast cancer (BC) is a prevalent human malignancy and a very common cause of cancer-related death among women worldwide. Currently, it is considered a multifactorial disease and patients with BC could have a wide range of clinical, pathological, and molecular characteristics. The Cancer Stem Cells (CSCs) hypothesis claims that tumors, as well as normal tissues, are formed from a group of cells called cancer stem cells or “cancer-initiating cells” through asymmetric cell division, simultaneously maintaining the stem population and generating multilineage differentiation. The hypothesis that tumors may originate from a rare population of CSCs has gained tremendous popularity in recent years and is supported extensively by several pioneering works. Cancer therapies targeting CSCs have unlimited potential for relapse free survival of cancer patients. As a result, knowledge of biological pathways that govern CSCs is very important and this review is focused on the biology of CSCs with special emphasis on breast CSCs, and recent advances in therapeutic approaches targeting them. Our aim is to stimulate further study of these agents that could become the basis for their use as stand-alone treatments or components of combination therapies effective against breast cancers. Methods: In this study, the articles published at intervals from 2012 to 2022 in the databases including Web of Science, PubMed, Science direct, Embase, Google scholar, SID and Iran-medex. The keywords including "stem cell", "targeting", "breast cancer", "treatment" were examined. Studies published in English and Persian were considered as eligible. Results: The higher resistance of BCSCs to standard therapies in comparison with other cells of the tumor bulk highlights the need for new therapies targeting the stem population. The identification of breast cancer stem-cell biomarkers may allow for direct assessment of therapeutic effects on this cell population. An agent that only targets cancer stem cells and not bulk tumor cells would be predicted to have only modest effects on tumor size but could have dramatic effects in preventing recurrence in the adjuvant setting. In contrast, agents which primarily affect bulk populations rather than cancer stem cells may cause tumor regression but may be less effective when administered in the adjuvant setting. In addition, cancer stem-cell regulatory pathways are highly interconnected, which suggests that the use of combinations of targeting agents may be necessary to effectively eliminate this cell population. Despite these challenges, the development of stem cell targeted therapeutics has the potential to significantly improve outcome for patients with both early-stage and advanced breast cancers. Conclusion: What seems to be increasingly clear is that CSCs are involved in tumor recurrence, metastasization, and drug resistance. Therefore, a high proportion of BCSCs have been associated with poor outcome. For this reason, many studies have focused on BCSCs analysis as well as on the identification of new drugs capable of eradicating this population. The existence of tumor initiating or cancer stem cells within tumors responsible in part of drug resistance and current treatment failure and recurrence. All of the presented targets here might be of use for the development of a BCSC-directed therapy, however we believe a combination of the pharmacological targets would be desirable since BCSC resistant clones may appear because of the selection pressure derived from monotherapy.
لیست مقالات
ثمین همایش، سامانه مدیریت کنفرانس ها و جشنواره ها - نگارش 34.4.5
